Hypoparathyroidism Pipeline Analysis report covers 5 drugs currently in different phases of development. Hypoparathyroidism is a rare condition that arises due to inadequate production, secretion, and activity of the parathyroid hormone. The decreased level of parathyroid hormone leads to low calcium levels as well as low potassium levels in the blood. The condition may be caused by injury to or removal of the parathyroid glands, genetic disorders such as DiGeorge syndrome: cancer radiation treatments or insufficient magnesium levels in the body. Symptoms include muscle spasms, muscle aches or cramps, tingling, burning, or numbness in the fingertips, toes, and lips, fatigue or weakness, painful menstruation, depression or anxiety, and brittle nails.
The report provides Hypoparathyroidism treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are EnteraBio Ltd., Amorphical Ltd., Ascendis Pharma, and Pharis Pharmaceuticals.
Scope:
The report provides Hypoparathyroidism treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are EnteraBio Ltd., Amorphical Ltd., Ascendis Pharma, and Pharis Pharmaceuticals.
Scope:
- By Company
- By Phase
- By Molecule Type
- By Region
- By Route of Administration
Table of Contents
1. Introduction
2. Disease Overview
4. Market Dynamics
5. Pipeline Analysis/Outlook
6. Company profiling
Companies Mentioned
- EnteraBio Ltd.
- Amorphical Ltd.
- Ascendis Pharma
- GC Pharma
- Pharis Pharmaceuticals
Methodology
LOADING...
